REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Lymphokine > Interferon > Alpha Or Leukocyte Alpha Or LeukocyteAlpha Or Leukocyte patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.07/05/07 - 20070154454 - Compositions and methods for treating poxvirus infection The present invention provides methods of treating a poxvirus infection, e.g., a vaccinia virus or a variola virus infection; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from a poxviral infection. The present ... 06/07/07 - 20070128162 - Alpha interferon variants The present invention provides biologically active variants of human α-2b-interferon. The variants contain carboxy terminus truncations when compared with the amino acid sequence of full-length human α-2b-interferon. It is the novel finding of the present invention that these truncated variants have the biological activity of full-length human α-2b-interferon. The invention ... 04/05/07 - 20070077225 - Continuous delivery methods for treating hepatitis virus infection The present invention provides methods of treating hepatitis virus infection. The methods generally involve administering an IFN-α by continuous delivery. Continuous delivery of IFN-α provides for a serum profile of IFN-α such that a sustained viral response is achieved. ... 03/29/07 - 20070071721 - Methods for treating viral infection using il-28 and il-29 IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof ... 03/29/07 - 20070071720 - Method of treating hepatitis b viral infection The present invention provides the use of PEG-IFN-α conjugates in association with ribavirin for the treatment of chronic hepatitis B infections. The present invention also provides a method for treating chronic hepatitis B infections in patients in need of such treating comprising administering an amount of PEG-IFN-α conjugate in association ... 03/22/07 - 20070065407 - Interferon-alpha polypeptides and conjugates The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the ... 03/08/07 - 20070053878 - Sars The invention relates to the field of virology. The invention provides an isolated essentially mammalian positive-sense single stranded RNA virus (SARS) within the group of coronaviuses and components thereof. ... 03/01/07 - 20070048282 - Albumin fusion proteins The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention ... 02/01/07 - 20070025966 - Interferon-alpha polypeptides and conjugates The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the ... 01/25/07 - 20070020235 - Interferon-alpha polypeptides and conjugates The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the ... 01/11/07 - 20070009480 - Low-toxicity, long-circulating human interferon-alpha analogs Interferon-alpha (IFNα) analog proteins modified by chemical attachment of at least one hydrophilic polymer moiety, such as polyethylene glycol chain, are described. In one embodiment, the IFNα analog protein has an amino acid sequence that differs from a native human IFNα interferon-alpha by one or more amino acid residues in ... 12/21/06 - 20060286070 - Methods related to immunostimulatory nucleic acid-induced interferon Methods and compositions are provided for extending the clinical utility of IFN-α in the treatment of a variety of viral and proliferative disorders. Among other aspects, the invention provides methods which increase the efficacy of IFN-α treatment and reduce IFN-α treatment-related side effects. In addition, methods are provided for supporting ... 12/07/06 - 20060275260 - Use of imatinib to treat liver disorders and viral infections The present invention relates to the use of imatinib for treating viral liver diseases and in particular for viral hepatitis. The invention provides the use of imatinib for inhibiting replication, transmission or both of hepatitis viruses. The invention further relates to the use of imatinib for inhibiting replication, transmission or ... 11/30/06 - 20060269517 - Use of alpha-glucosidase inhibitors to treat alphavirus infections The present invention provides methods for treating a flavivirus infection, including hepatitis C virus (HCV) infection, in an individual suffering from a flavivirus infection. In some embodiments, the methods involve administering to an individual in need thereof an effective amount of an agent that inhibits enzymatic activity of a membrane-bound ... 11/16/06 - 20060257365 - Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection There is disclosed a method for treating a patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using a therapeutically effective amount of ribavirin and a therapeutically effective amount of interferon-alpha for a time period of from 20 up to 80 weeks. ... 11/02/06 - 20060246035 - Methods and products related to treatment and prevention of hepatitis c virus infection The invention provides methods for identifying and treating subjects having hepatitis C infections. In some instances, the subjects are those that are non-responsive to non-CpG therapy. Preferably, the subjects are treated with C class CpG immunostimulatory nucleic acids having a semi-soft backbone. ... 10/12/06 - 20060228333 - Methods for control of tumors and chronic infections by modulating immunologically informed carriers homing to tolerogenic organs or tissues Methods for treating a patient after transplantation of a liver are presented which facilitate acceptance of the donor liver and treat the underlying disease or disorder that led to the transplant. A patient with a chronic viral infection is treated by inducing tolerance to the donor liver and suppressing tolerance ... 09/14/06 - 20060204474 - Treatment of epithelial layer lesions Methods for the treatment of lesions originating in an epithelial layer, particularly diseases of the epithelium of the skin, bladder, oral mucosa, vagina and cervix are described. Also described are uses and formulations for the treatment of lesions originating in an epithelial layer. ... 09/07/06 - 20060198824 - Treatments for flaviviridae virus infection The present invention provides methods for treating infections, in a host, by viruses belonging to the Flaviviridae family, such as HCV, comprising administering an Ara-C homologue to the host. ... 09/07/06 - 20060198823 - Compositions and methods for treating viral infections The present invention provides methods of treating a virus infection, and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from a coronavirus infection. The present invention further provides methods of reducing the risk that ... 08/24/06 - 20060188478 - Glycosylated interferon This invention provides for human interferon-α which includes novel glycosylation structures. ... 08/24/06 - 20060188477 - Use of interferon alpha 5 in the treatment of viral liver diseases The invention relates to the use of interferon alpha 5 in the treatment of viral hepatopathies. The invention describes the reduced synthesis of IFNα5 in the livers of patients with hepatitis C in comparison to healthy livers. The sub-type of IFN expressed in said healthy livers corresponded only to the ... 07/27/06 - 20060165655 - Therapeutic furopyrimidines and thienopyrimidines The invention provides compounds of formula I, II, and III as described herein, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates that are useful for preparing the compounds. The compounds of formula I, II, and III are useful as anti-viral agents and/or as anti-cancer agents. ... 07/20/06 - 20060159658 - Methods of treating disease with glycosylated interferon This invention includes methods for treating conditions with pharmaceutical compositions that comprise glycosylated interferon alpha. Pharmaceutical compositions that can be employed in the present invention include glycosylated interferon alpha 2 species in combination with pharmaceutical carriers, pharmaceutical excipients and/or other agents. ... 06/22/06 - 20060134064 - Combined treatment with interferon-alpha and an epidermal growth factor receptor kinase inhibitor The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and IFNα combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. ... 05/18/06 - 20060104948 - Interferon immunotherapy A method for reducing the recurrence of a resectable malignant tumor includes administering an immunostimulatory dosage of an α-interferon composition, then surgically resecting the malignant tumor. A method for treating a human patient having a non-resectable malignant tumor includes administering an immunostimulatory dosage of an α-interferon composition to the patient ... 03/23/06 - 20060062762 - Method of cancer treatment; method of diabetes treatment; method of multiple sclerosis treatment; method of interstitial cystitis treatment; method of acquired immune deficiency syndrome treatment; and method of herpes treatment A method treating diseases including cancer comprising administering a drug which provides interferon alpha once inside the body, administering a vaccine containing tumor necrosis factor, and administering a predetermined quantity of an anti-viral drug. The three drugs work together to strengthen the patient's immune system, make the infection or virus ... 03/23/06 - 20060062761 - Modified interferon alpha with reduced immunogenicity The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular to ... 03/16/06 - 20060057107 - Combination treatment for multiple sclerosis The present invention provides for the treatment of multiple sclerosis by combination therapies of CD52 specific antibodies, such as CAMPATH-1H, with either a Type 1 interferon or coploymer-1. ... 02/09/06 - 20060029573 - Pegylated interferon alpha-1b The invention provides PEG-IFN α-1b conjugates, where a PEG moiety is covalently bound to Cys86 of human IFN α-1b conjugates. A pharmaceutical composition and a method for treating inflammatory diseases, infections, and cancer are also provided. The invention further relates to a method for the modification of interferons by conjugation ... 02/02/06 - 20060024272 - C-terminally truncated interferon The invention described herein provides a C-terminally truncated interferon having enhanced biological activity and the polynucleotides encoding such interferon. Also provided are methods for producing and using such truncated interferon. ... 01/26/06 - 20060018876 - Treatment of diseases caused by viral infection A method of prophylactic and/or therapeutic treatment of a mammal for a disease that is caused by a Ljungan virus infection, such as Myocarditis, Cardiomyopathia, Guillain Barré Syndrome, and Diabetes Mellitus, Multiple Sclerosis, Chronic Fatigue Syndrome, Myasthenia Gravis, Amyothrophic Lateral Sclerosis, Dermatomyositis, Polymyositis, Spontaneous Abortion, Intrauterine Death, Preeclampsia, Sudden Infant ... 11/24/05 - 20050260156 - Modified vaccinia virus ankara for the vaccination of neonates The invention relates inter alia to a method for inducing a long-term protection in an animal against foreign antigens and tumor antigens comprising the step of administering to the animal at least one factor selected from type I interferons and Flt-3, and to a method for inducing a long-term increase ... 11/10/05 - 20050249704 - Method of treating autoimmune diseases with interferon-beta and il-2r antagonist Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments ... 10/27/05 - 20050238621 - Melanoma therapy Methods for treating treatment-naive as well as treatment-experienced patients having melanoma to increase the progression-free survival time involving administering a therapeutically effective amount of pegylated interferon-alpha, e.g., preferably pegylated interferon alpha-2b, as adjuvant therapy to definitive surgery are disclosed. ... 10/20/05 - 20050232899 - Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b Stable aqueous formulations which are free of products derived from human or animal origin and which maintain high biological activity and high chemical and physical stability of alpha-type interferon, and proteins in general, for an extended period of time. Methods of producing stable aerosol formulations of the same for delivery ... 09/29/05 - 20050214255 - N-acylated chitinous polymers and methods of use thereof The invention pertains to N-acetylated, N, O-carboxyalkylchitosans and methods for using the chitosans to treat disorders, such as cancer, nervous system disorders, urinary tract disorders, and reproductive tract disorders. ... 08/11/05 - 20050175586 - Method of treating anemia caused by ribavirin treatment of hepatitis c using erythropoietin alpha Claimed and disclosed is a new use for a previously approved drug: erythropoietin. The present invention teaches using Erythropoetin to treat anemia caused by the combined treatment of Ribavirin and alpha-interferon. Erythropoetin has previously been approved for the treatment of anemia caused by cancer chemotherapy, renal failure and HIV. It ... 08/04/05 - 20050169888 - Methods related to immunostimulatory nucleic acid-induced interferon Methods and compositions are provided for extending the clinical utility of IFN-α in the treatment of a variety of viral and proliferative disorders. Among other aspects, the invention provides methods which increase the efficacy of IFN-α treatment and reduce IFN-α treatment-related side effects. In addition, methods are provided for supporting ... ### FreshPatents.com Support |